24/7 Clients Support
| Brand Name | ABIRALIEVA 250 MG |
| Composition | Abiraterone Acetate — 250 mg |
| Manufacture By | Allieva Pharma Private Limited |
| Form | Tablet |
| Packing | Btl (120 Tab) |
| Country Of Origin | India |
| Description | Abiralieva 250 mg contains Abiraterone Acetate, a prodrug that converts to abiraterone in the body. It works by inhibiting the CYP17 enzyme, which is crucial for androgen (male hormone) production in testes, adrenal glands, and prostate tumor tissues. Since prostate cancer cells grow by using androgens, this inhibition helps slow cancer progression. Abiraterone is always used together with Prednisolone/Prednisone and in combination with Androgen-Deprivation Therapy (ADT). |
| Uses | ➢ Abiralieva (Abiraterone) is prescribed for: 1. Metastatic Castration-Resistant Prostate Cancer (mCRPC) Cancer that grows even after testosterone suppression. 2. Metastatic High-Risk Castration-Sensitive Prostate Cancer (mCSPC) Used early along with ADT. 3. Hormonal therapy in advanced prostate cancer As part of combination therapy to reduce tumor progression. |
| Side Effects | ➢Common Side Effects High blood pressure Low potassium levels Swelling of legs/ankles (fluid retention) Fatigue Hot flashes Nausea or indigestion Muscle or joint pain ➢Serious Side Effects Liver enzyme abnormalities Irregular heartbeat Adrenal insufficiency Severe hypokalemia Trouble breathing due to fluid buildup ➢ Seek immediate medical help if: Yellowing of skin/eyes Severe dizziness or fainting Fast or irregular heartbeat Unexpected weight gain due to fluid |
| Dosage | ➢ Standard Adult Dose 1000 mg daily (i.e., 4 tablets of Abiralieva 250 mg) Take once daily on an empty stomach No food 2 hours before taking No food 1 hour after taking ➢ Plus Prednisolone/Prednisone 5–10 mg daily ➢ Additional Notes Swallow whole, do not crush. Continue androgen-deprivation therapy (ADT). Liver tests and potassium levels must be monitored regularly. |